Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL3: EOX chemotherapy with or without panitumumab in advanced oesophago-gastric cancer
2007-005976-15Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in gastric adenocarcinoma, adenocarcinoma of the lower esophagus, Esophago-Gastric Adenocarcinoma and 3 more (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Overall survival. Started Feb 2008; status: completed.
02
Drugs
panitumumab
03
Conditions
gastric adenocarcinomaadenocarcinoma of the lower esophagusEsophago-Gastric Adenocarcinomaesophageal undifferentiated carcinomaUndifferentiated carcinoma of the oesophagogastric junction
Beyond the preview
Go deeper on 2007-005976-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005976-15.